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Paget's Disease 
Stephen M. Krane, MD* 
fd. Note - This overview was originally presented at the 
International Symposium on Clinical Disorders of Bone 
and Mineral Metabolism, May 9-13,1983. The following 
list indicates the presentations given in this session at the 
Symposium and the contents ofthe corresponding chap-
ter in the Proceedings of the Symposium published by 
Excerpta Medica. The numbers in parentheses refer to 
pages in this volume. Complete information about the 
contents of the Proceedings can be found atthe back of 
this issue. 
What is the etiology of Paget's disease and can we cure it? 
F.R. Singer and B.G. Mills (380) 
Do calcitonins help Paget's disease of bone? O.L.M. Bij-
voet (389) 
Bisphosphonate treatment for Paget's disease of bone. 
O.L.M. Bijvoet (389) 
Mithramycin treatment of Paget's disease of bone explo-
ration of combined therapies—particularly sodium etid-
ronate (EHDP). W.G. Ryan (395) 
Paget's disease of bone has been studied extensively by 
many investigators interested in metabolic bone dis-
eases. Yet Albright and Reifenstein (1) pointed out in 
1948 that Paget's disease is not generalized and that nor-
mal bone can always be identif ied. The fact that Paget's 
disease is localized to some but not to all bones was 
offered as "strong evidence against its being a metabolic 
or endocrine disorder." Whether or not Paget's disease 
does belong in the category of metabolic bone diseases, 
it has been possible to learn a great deal about bone 
turnover in this disorder and successfully use therapeu-
tic agents to help patients clinically. 
We assume that the initial event in Paget's disease is a 
focal resorption of existing normal bone (2). Histologi-
cally, this excessive resorption is shown by the increase 
in the scalloped resorption spaces (Howship's lacunae) 
f i l led with active osteoclasts that are larger and more 
multinucleated. Even in the earliest biopsies of Pagetic 
lesions, however, increased osteoblastic activity is evi-
dent with the deposition of lamellar or woven bone 
adjacent to areas of resorption, frequently on opposite 
surfaces. These events have been interpreted as indicat-
ing a marked increase in the "b i r th rate" of the basic 
multicellular units of bone (3). Although bone resorp-
t ion and formation are both increased, the relative 
increase in resorption is greater than that of normal 
bone. The uninvolved non-Pagetic bone may not be 
entirely normal and may show increased resorption and 
osteoid surfaces. The latter changes have been inter-
preted as due to secondary hyperparathyroidism (3). 
If resorption is the initial event in Paget's disease and the 
increases in bone formation are coupled to increases in 
resorption, then it would fol low that if one decreases the 
resorption rate, the formation rateshould also decrease. 
In fact, it has been possible to decrease bone resorption 
in Paget's disease by using three different types of agents 
(calcitonins, diphosphonates, and mithramycin). Indices 
of bone formation decrease later than those of bone 
resorption. Although each of these drugs reduces osteo-
clast function and possibly the generation of new osteo-
clasts f rom precursor cells, the activity of the disease 
eventually returns to pretreatment levels after therapy is 
discontinued. The Pagetic lesion therefore is not cured. 
Recent evidence has suggested that Paget's disease is due 
to infection of osteoclasts or osteoclast precursors by a 
virus possibly related to measles or respiratory syncytial 
virus. F.R. Singer and B.G. Mills (pp. 380 ff.) presented the 
evidence for viral infection of Pagetic cells and discussed 
the problems in identifying possible agents. If a virus is 
definitively identif ied, it will still be essential to prove that 
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Radiograph of the pelvis and hips of a patient w i th Paget's disease of 
bone. The whole r ight hemipelvis and proximal femur is involved. The 
right hip joint has the typical appearance of Pagetic coxopathy wi th loss 
of apparent jo int space over the entire articular circumference of the 
femoral head and acetabular protrusion. In addi t ion, there is a patho-
logical fracture (arrow) of the right pubic ramus. These illustrate com-
mon complications of Paget's disease. 
this agent is the cause of the disease and not simply a 
passenger. If the former is the case, Paget's disease can be 
cured only if the putative virus is eliminated or if the 
deleterious consequences ofsuch infection (altered pro-
liferation and function of bone cells) are reversed. 
At present, we must treat the clinical problems of Paget's 
disease (Table). Al though most patients are asympto-
matic or have relatively little involvement, others must 
be treated with calcitonin, diphosphonates (bisphos-
phonates) or mithramycin, or possibly combinations of 
these drugs. Not all clinical problems are responsive to 
drug therapy. For example, it is probable that joint dis-
ease such as Pagetic coxopathy, once developed, wil l not 
be reversed by medical management but will eventually 
require and respond to total hip replacement. However, 
TABLE 
c l in ica l Problems in Patients with Paget's Disease of Bone 
1. Pain over lesions 
2. Deformit ies 
3. Joint disease 
4. Neural compression 
5. Propensity to fracture 
6. Vascular effects: high bone f low, high cardiac output , 
"s tea l " syndromes. 
7. Disabling fatigue 
8. Hypercalcemia and hypercalciuria 
9. Hyperuricemia 
10. Tumors: reparative granulomas, malignant neoplasms 
Other features are responsive, particularly pain over 
lesions demonstrable radiologically or by bone scan. 
Certain aspects of the use of calcitonins were reviewed 
by Nagant de Deauxchaisnes (pp. 384 ff.). He described 
the success of calcitonins in improving the focal lesions 
with apparent healing of the osteolytic disease and 
replacement with mineralized bone. Bijvoet (pp. 389 ff.) 
discussed the use of the bisphosphonates and empha-
sized their extraordinary potency in inhibit ing bone 
resorption. This has been demonstrated in numerous 
careful studies with etidronate disodium and is reflected 
in the normalization of the abnormally high urinary 
hydroxyproline excretion. In Bijvoet's experience, use of 
etidronate disodium results in clinical improvement in 
most instances, although some individuals have a tem-
porary increase in bone pain. Fractures were not a prob-
lem in his series. Osteolytic Pagetic lesions increased in 
some individuals, as stressed by Nagant de Deuxchaisnes. 
In contrast, APD (disodium [3-amino-1 hydroxypropyl-
idene]-1, 1-bisphosphonate), the most potent of the 
available bisphosphonates appears to arrest osteolytic 
lesions and helps to fill in defects. Unfortunately, APD has 
not been approved for use in most countries, including 
the US. Experience with mithramycin was reviewed by 
Ryan (pp. 395 ff.). Although this drug effectively reduces 
abnormal chemical findings in Paget's disease and improves 
symtoms and abnormal bone scans, it is potentially the 
most toxic of available drugs and must be used with 
caution. The long-term remissions that have occasionally 
been observed after a brief course of therapy have pro-
vided impetus for study of further potential uses of 
mithramycin alone or in combination with other agents. 
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